DECA Stock Forecast 2025-2026
Distance to DECA Price Targets
DECA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Denali Capital (DECA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on DECA and similar high-potential opportunities.
Latest DECA Stock Price Targets & Analyst Predictions
DECA has shown a year-to-date change of 1.8% and a 1-year change of 55.0%, reflecting upward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for DECA. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
DECA Analyst Ratings
DECA Price Target Range
Latest DECA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for DECA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|
Denali Capital Acquisition Corp. (DECA) Competitors
The following stocks are similar to Denali Capital based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Denali Capital Acquisition Corp. (DECA) Financial Data
Denali Capital Acquisition Corp. has a market capitalization of $40.19M with a P/E ratio of 71.1x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +1.5%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Denali Capital Acquisition Corp. (DECA) Business Model
About Denali Capital Acquisition Corp.
Facilitates mergers and acquisitions for growth companies.
Denali Capital Acquisition Corp. operates as a special purpose acquisition company (SPAC), raising capital through an initial public offering (IPO) to acquire or merge with growth-oriented businesses. It generates revenue primarily through the successful acquisition of these companies, which allows them to go public without the traditional IPO process.
The company targets various industries, providing flexibility in its investment approach. Denali Capital Acquisition Corp. is part of a growing trend of SPACs, appealing to investors seeking efficient pathways to public markets while also capitalizing on strategic mergers and acquisitions.
Denali Capital Acquisition Corp. (DECA) Latest News & Analysis
Denali Capital Acquisition Corp. Announces Extension of Deadline to Complete Business Combination
15 days agoDenali Capital Acquisition Corp. has extended its deadline to April 11, 2025, by depositing $15,063.74 into its trust account, funded by a convertible note from Scilex Holding Company.
Denali Capital's funding extension indicates a delay in completing a business combination, affecting investor confidence and potential returns. The convertible note highlights reliance on Scilex's support.
Semnur Pharmaceuticals to go public via SPAC merger with Denali Capital in $2.5 bln deal
6 months agoSemnur Pharmaceuticals will go public through a $2.5 billion merger with Denali Capital Acquisition Corp, as announced by the companies.
The $2.5 billion merger provides Semnur Pharmaceuticals access to capital and market exposure, potentially increasing Scilex Holding's value and impacting investors' portfolios.
Denali Capital Acquisition Corp. shareholders approved an extension for the initial business combination deadline from July 11, 2024, to April 11, 2025, with options for monthly extensions up to nine times.
The extension for Denali Capital Acquisition Corp. allows more time to secure a business combination, potentially increasing the company's value and reducing the risk of liquidation for shareholders.
Semnur Pharmaceuticals to go public in SPAC deal of up to $2 billion with Denali Capital
8 months agoSemnur Pharmaceuticals plans to go public via a merger with Denali Capital Acquisition Corp, with the deal valued at up to $2 billion.
Semnur Pharmaceuticals' merger with Denali Capital could unlock significant capital for growth, impacting market competition and investor sentiment in the biotech sector.
Non-Opioid Pain Therapy-Focused Semnur Pharmaceuticals Strikes $2B SPAC Deal For NASDAQ Debut
8 months agoSemnur Pharmaceuticals Inc. and Denali Capital Acquisition Corp. have signed a letter of intent for a proposed business combination.
The proposed business combination may enhance Scilex's market position and growth potential, influencing stock performance and investor sentiment in both companies.
Semnur Pharmaceuticals, a subsidiary of Scilex Holding (Nasdaq: SCLX), plans to merge with Denali Capital Acquisition Corp (Nasdaq: DECA) at a pre-transaction value of $2 billion, aiming for up to $40 million in proceeds.
The proposed merger values Semnur at $2 billion, highlighting its growth potential in non-opioid pain management. This could enhance Scilex's market position and investor confidence.
Frequently Asked Questions About DECA Stock
What is Denali Capital Acquisition Corp.'s (DECA) stock forecast for 2025?
Analyst forecasts for Denali Capital Acquisition Corp. (DECA) are not currently available. The stock is trading at $12.09.
Is DECA stock a good investment in 2025?
Analyst ratings for DECA are not currently available. The stock is currently trading at $12.09. Investment decisions should be based on thorough research and your personal financial goals. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for DECA stock?
Price predictions from Wall Street analysts for DECA are not currently available. The stock is trading at $12.09.
What is Denali Capital Acquisition Corp.'s business model?
Denali Capital Acquisition Corp. operates as a special purpose acquisition company (SPAC), raising capital through an initial public offering (IPO) to acquire or merge with growth-oriented businesses. It generates revenue primarily through the successful acquisition of these companies, which allows them to go public without the traditional IPO process.
What is the highest forecasted price for DECA Denali Capital Acquisition Corp.?
Price targets from Wall Street analysts for DECA are not currently available. The stock is trading at $12.09.
What is the lowest forecasted price for DECA Denali Capital Acquisition Corp.?
Price targets from Wall Street analysts for DECA are not currently available. The stock is trading at $12.09.
What is the overall DECA consensus from analysts for Denali Capital Acquisition Corp.?
Analyst ratings for DECA are not currently available. The stock is trading at $12.09.
How accurate are DECA stock price projections?
Stock price projections, including those for Denali Capital Acquisition Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
